Recro Pharma

Societal CDMO, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Societal CDMO, Inc. is a bi-coastal CDMO with capabilities spanning pre-investigational new drug (IND) development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a focus on small molecules. With expertise in solving complex problems, the company provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill and finish, lyophilization, packaging, and logistics services to the pharmaceutical market. The company was founded in 2007. It has sites in Gainesville, GA, San Diego, CA, and is headquartered in Exton, PA.

With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society

Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation

Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript

Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million

Recro Reports Fourth Quarter and Year End 2021 Financial Results

Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern

Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new formulation development and cGMP manufacturing contract from a key department of the United States government. The contract focuses on supporting clinical development of a topical dermal treatment for the prevention of skin cancer.

Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention

Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations

Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego

SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference. The conference, which will take place January 10-13, 2022, is being conducted with a virtual format.

Recro to Present at H.C. Wainwright BioConnect 2022 Conference

Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.

Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?

Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript

Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities

Recro Reports Third Quarter 2021 Financial Results

Agreement Establishes Recro as Commercial Supplier for Otsuka

Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka

Recro Pharma Inc (NASDAQ: REPH) has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH).  The new contract is an individual $1.87 million task order that falls under an existing NIH parent contract previously awarded to IriSys, the San Diego-based CDMO that Recro recently acquired.

Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic

New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturing” Contract with NIH New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturing” Contract with NIH

Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic

Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego

Recro Reports Inducement Grants For New Staff

Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.

Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?

Investment in Renewable Energy Credits Represents Key Component of Company's Ongoing Environmental Sustainability Program Investment in Renewable Energy Credits Represents Key Component of Company's Ongoing Environmental Sustainability Program

Recro Signs Renewable Energy Agreement With Georgia Power

Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade

Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth

Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS

Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms

Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO

EXTON, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it has signed a non-binding letter of intent (“the LOI”) for its acquisition of a full service CDMO with capabilities that range from formulation development to commercial manufacturing for various dosage forms including oral liquids, sterile injectables, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles (the “Target”).

Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO

Recro Pharma, Inc. (REPH) CEO David Enloe on Q2 2021 Results - Earnings Call Transcript

Shares of Recro Pharma (NASDAQ:REPH) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 112.00% over the past year to $0.03, which beat the estimate of ($0.11).

Recro Pharma: Q2 Earnings Insights

Q2 2021 Highlighted by Revenues of $18.0 Million, an Increase of 16% Compared to Q2 2020 Revenue

Recro Reports Second Quarter 2021 Financial Results

Conference Call and Webcast Scheduled for Monday, August 9, 2021 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Monday, August 9, 2021 at 4:30 p.m. Eastern

Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021

GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a development and cGMP manufacturing agreement with a new client. Under the terms of the agreement, Recro will provide early-stage development and manufacturing services to support the client's ongoing clinical development of an orally administered, minimally-absorbed investigational compound.

News for Recro Pharma Stock (REPH)